Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7457566 | 0.90 | P2RX7 (0.47) | P2RX7 | |
| SCHEMBL7690104 | 0.89 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL7690960 | 0.89 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL7691647 | 0.89 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL7513375 | 0.89 | P2RX7 (0.46) | P2RX7 | |
| SCHEMBL5816839 | 0.88 | P2RX7 (0.58) | P2RX7 | |
| SCHEMBL6572601 | 0.88 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL7685711 | 0.88 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL7689756 | 0.88 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL7691899 | 0.87 | P2RX7 (0.48) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193414-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | US | claimed |
| EP-1240132-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | claimed |
| WO-2001042194-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | claimed |
| US-20020193414-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | US | disclosed |
| EP-1240132-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001042194-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193414-A1 | Adamantane derivatives | APP, ADORA1, ADAM17 | P2RX7 894/4885P2RY12 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.